Comparative Pharmacology
Head-to-head clinical analysis: OXYTETRACYCLINE HYDROCHLORIDE versus PANMYCIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OXYTETRACYCLINE HYDROCHLORIDE versus PANMYCIN.
OXYTETRACYCLINE HYDROCHLORIDE vs PANMYCIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Oxytetracycline binds reversibly to the 30S ribosomal subunit, inhibiting protein synthesis by blocking the attachment of aminoacyl-tRNA to the mRNA-ribosome complex.
Tetracycline antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-tRNA from attaching to the A site.
250-500 mg orally every 6 hours or 1-2 g/day divided every 12 hours intravenously.
250-500 mg PO q6h or 500 mg to 1 g IV q6h; maximum 4 g/day
None Documented
None Documented
6-10 hours (prolonged to 48-100 hours in renal impairment; consider dose adjustment in CrCl <50 mL/min)
Terminal elimination half-life is 6-8 hours in patients with normal renal function. Half-life is significantly prolonged (up to 80 hours) in anuria, requiring dose adjustment.
Renal (60-70% unchanged by glomerular filtration); biliary/fecal (20-35%)
Primarily renal excretion of unchanged drug via glomerular filtration; 80-90% recovered in urine within 24 hours. Biliary/fecal excretion accounts for <5%.
Category D/X
Category C
Tetracycline Antibiotic
Tetracycline Antibiotic